As demonstrated above, UDCA treatment could reduce the serum ALT and AST levels, and improve hepatic inflammation in a dose-dependent pattern; thus, we further evaluated the effect of UDCA on the intestinal barrier function and levels of serum endotoxemia and inflammatory cytokines in NASH mice. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatohepatitis.